Following Thanksgiving week we have just one IPO due. Phase 1-ready biotech Nuvectis Pharma ($NVCT) plans to raise $30 million at a $160 million market cap. Be aware there is still a chance that a handful of SPACs will price during the week.
Phase 1-ready biotech Nuvectis Pharma ($NVCT)
plans to raise $30 million at a $160 million market cap. The company is initially focused the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. Nuvectis is currently developing two preclinical candidates, with its lead candidate expected to begin a Phase 1 trial in the 4Q21
Street research is expected for 11 companies, and lock-up periods will be expiring for up to 11 companies.
Source: Renaissance Capital
From The TradersCommunity News Desk